文献简介

出版社:Springer International Publishing Switzerland

作  者:Farah A. Moustafa • Laura F. Sandova

编  号:10.1007/s40265-014-0281-x

关键字:Rosacea,Treatment

年  份:2014   点击量:1037

文献摘要 全文翻译

Abstract

Rosacea is a chronic inflammatory skin condition that negatively impacts patients’ quality of life. We sought to review important aspects of the pathogenesis of rosacea and the role of new treatment options in its management. New, emerging treatments show promise; however, quality randomized controlled trials for many of these drugs are lacking. Brimonidine tartrate is an effective newly approved treatment for erythematotelangiectatic rosacea. Topical oxymetazoline has potential for the treatment of erythematotelangiectatic rosacea, with efficacy described in case reports and randomized controlled trials currently underway. Both oral and topical ivermectin have been studied for the treatment of papulopustular rosacea, both showing benefit; however, only topical ivermectin 1 % cream has been studied in randomized controlled trials. As our understanding of the etiology of rosacea continues to evolve, so will our options for therapeutic interventions. Further studies need to be performed to assess the long-term safety and efficacy of these treatments.

摘要

酒渣鼻是一种慢性炎症性皮肤病,严重影响患者的生活质量。本文回顾酒渣鼻发病机制的重要方面,以及新的治疗方法。新的治疗方法显示出良好的治疗效果;但是缺乏这些药物高质量的随机对照试验。酒石酸溴莫尼定是最新批准用于治疗红斑血管扩张型酒渣鼻的有效方法。外用羟甲唑啉可用于治疗红斑血管扩张型酒渣鼻,并且在病例报道以及目前正在进行的随机对照试验中被证明具有较好疗效。口服和外用伊维菌素已被研究用于治疗丘疹脓疱性酒渣鼻,二者均显示较好疗效; 然而,在随机对照试验中仅对局部应用1%伊维菌素乳膏的疗效进行了研究。我们对酒渣鼻的病因的不断了解,其治疗措施的也不断改进。今后需要进一步的研究评估这些治疗方法长期的有效性和安全性。